Starting July 1, a new Medicare pilot program will allow some adults aged 65 and older to access GLP-1 weight-loss drugs for just $50 per month.
The initiative, called Medicare GLP-1 Bridge, aims to reduce financial barriers for seniors struggling with obesity.
>>> Manchester United Signs Spanish Defender Andrea Medina
Kathryn, a retiree who worked in healthcare, has experienced what she calls “cyclical weight-loss, weight-gain” throughout her life.
At her heaviest, the 5ft 1in woman weighed 220lbs.
After starting a GLP-1 drug about two years ago, she now weighs 133lbs and reports improved blood pressure and cholesterol.
However, the monthly cost of $450 for Zepbound has forced her to stretch doses and forgo retirement travel.
The program covers three drugs: Foundayo, Wegovy, and Zepbound.
Eligible participants must have Medicare Part D, a body mass index of 35 or higher, and cannot have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, as those conditions may already be covered.
According to a KFF Health survey, about 5 million US adults aged 65 and older were taking a GLP-1 drug for weight loss or a chronic condition in fall 2025.
Dr. Christopher Weber, an internist in Milwaukee who treats obesity patients, notes that seniors are more likely than younger adults to stop using the drugs due to cost.
>>> Jamir Nazir Wins Commonwealth Short Story Prize Amid AI Allegations
Logistical Concerns and Temporary Nature
Doctors have raised concerns about the program's implementation.
Dr. Annie Moore, an internist at CU Health in Denver, called it “a huge social and healthcare experiment,” questioning whether the CMS website, pharmacies, and health systems can efficiently process prior authorizations.
